From: A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness
 | Moderate pandemics (R = 1.9 and CFR = 0.25%) | ||
---|---|---|---|
Scenarios | SD and AV intervention | Life years saved (LYS) per 10,000 population | |
Pre-emptive vaccination | Reactive vaccination | ||
Scenario 1: no pandemic | none | - | - |
 | Pre-emptive + Reactive vaccination | Reactive vaccination | |
Scenario 2: pandemic with virus which does not match pre-emptive vaccine i.e. vaccine efficacy of 0% | none | 4* | 4* |
8 weeks SD + AV | 253 | 253 | |
Sustained SD + AV | 421 | 421 | |
 | Pre-emptive vaccination | Reactive vaccination | |
Scenario 3: pandemic with virus which matches pre-emptive vaccine with efficacy of 30% | none | 312 | 4* |
8 weeks SD + AV | 415 | 253 | |
Sustained SD + AV | 429 | 421 | |
 | Pre-emptive vaccination | Reactive vaccination | |
Scenario 4: pandemic with virus which matches pre-emptive vaccine with efficacy of 75% | none | 453 | 4* |
8 weeks SD + AV | 460 | 253 | |
Sustained SD + AV | 462 | 421 | |
 | Extreme pandemics (R = 2.7 and CFR = 1.5%) | ||
Scenarios | SD and AV intervention | Total cost ($) per 10,000 population | |
Pre-emptive vaccination | Reactive vaccination | ||
Scenario 1: no pandemic | none | - | - |
 | Pre-emptive + Reactive vaccination | Reactive vaccination | |
Scenario 2: pandemic with virus which does not match pre-emptive vaccine i.e. vaccine efficacy of 0% | none | 9* | 9* |
8 weeks SD + AV | 1,219 | 1,219 | |
Sustained SD + AV | 2,720 | 2,720 | |
 | Pre-emptive vaccination | Reactive vaccination | |
Scenario 3: pandemic with virus which matches pre-emptive vaccine with efficacy of 30% | none | 1,680 | 9* |
8 weeks SD + AV | 2,719 | 1,219 | |
Sustained SD + AV | 3,134 | 2,720 | |
 | Pre-emptive vaccination | Reactive vaccination | |
Scenario 4: pandemic with virus which matches pre-emptive vaccine with efficacy of 75% | none | 3,499 | 9* |
8 weeks SD + AV | 3,507 | 1,219 | |
Sustained SD + AV | 3,510 | 2,720 |